Immunosuppressive activities of adenosine in cancer

Current Opinion in Pharmacology

Volumn 29, Issue , 2016, Pages 7-16

  Allard, Bertrand ^a,b   Beavis, Paul A ^c,d   Darcy, Phillip K ^c,d   Stagg, John ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CD39 ANTIGEN; ECTO 5' NUCLEOTIDASE; MONOCLONAL ANTIBODY; ANTIBODY; ANTINEOPLASTIC AGENT; PURINERGIC RECEPTOR;

ARTICLE; BIOACCUMULATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG MECHANISM; DRUG TARGETING; EFFECTOR CELL; ENDOTHELIUM CELL; HUMAN; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DRUG DESIGN; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

5'-NUCLEOTIDASE; ADENOSINE; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; NEOPLASMS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A2B; RECEPTORS, PURINERGIC;

EID: 84971247500     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2016.04.001     Document Type: Review

References (107)

1. D.H. Munn, and V. Bronte Immune suppressive mechanisms in the tumor microenvironment Curr Opin Immunol 39 2016 1 6
2. S.L. Topalian, C.G. Drake, and D.M. Pardoll Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 2015 450 461
3. K.M. Mahoney, P.D. Rennert, and G.J. Freeman Combination cancer immunotherapy and new immunomodulatory targets Nat Rev Drug Discov 14 2015 561 584
4. D. Allard, B. Allard, P.-O. Gaudreau, P. Chrobak, and J. Stagg CD73-adenosine: a next-generation target in immuno-oncology Immunotherapy 8 2016 145 163
5. L. Antonioli, G.G. Yegutkin, P. Pacher, C. Blandizzi, and G. Haskó Anti-CD73 in cancer immunotherapy: awakening new opportunities Trends Cancer 2 2016 95 109
6. J.-F. Chen, H.K. Eltzschig, and B.B. Fredholm Adenosine receptors as drug targets - what are the challenges? Nat Rev Drug Discov 12 2013 265 286
7. H.K. Eltzschig Extracellular adenosine signaling in molecular medicine J Mol Med 91 2013 141 146
8. T.M. Palmer, and M.A. Trevethick Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction Br J Pharmacol 153 2008 S27 S34
9. B.B. Fredholm Adenosine, an endogenous distress signal, modulates tissue damage and repair Cell Death Differ 14 2007 1315 1323
10. A. Ohta, and M. Sitkovsky Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage Nature 414 2001 916 920
11. B. Allard, M. Turcotte, and J. Stagg CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth J Biomed Biotechnol 2012 2012 485156
12. R.D. Leone, Y.-C. Lo, and J.D. Powell A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy Comput Struct Biotechnol J 13 2015 265 272
13. A. Young, D. Mittal, J. Stagg, and M.J. Smyth Targeting cancer-derived adenosine: new therapeutic approaches Cancer Discov 4 2014 879 888
14. D. Jin, J. Fan, L. Wang, L.F. Thompson, A. Liu, B.J. Daniel, T. Shin, T.J. Curiel, and B. Zhang CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression Cancer Res 70 2010 2245 2255
15. J. Stagg, U. Divisekera, H. Duret, T. Sparwasser, M.W.L. Teng, P.K. Darcy, and M.J. Smyth CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis Cancer Res 71 2011 2892 2900
16. B. Allard, S. Pommey, M.J. Smyth, and J. Stagg Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs Clin Cancer Res 19 2013 5626 5635
17. S.F. Häusler, I.M. del Barrio, J. Diessner, R.G. Stein, J. Strohschein, A. Hönig, J. Dietl, and J. Wischhusen Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion Am J Transl Res 6 2014 129 139
18. J. Stagg, U. Divisekera, N. McLaughlin, J. Sharkey, S. Pommey, D. Denoyer, K.M. Dwyer, and M.J. Smyth Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis Proc Natl Acad Sci U S A 107 2010 1547 1552
19. P.A. Beavis, N. Milenkovski, M.A. Henderson, L.B. John, B. Allard, S. Loi, M.H. Kershaw, J. Stagg, and P.K. Darcy Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses Cancer Immunol Res 3 2015 506 517
20. D. Mittal, A. Young, K. Stannard, M. Yong, M.W.L. Teng, B. Allard, J. Stagg, and M.J. Smyth Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor Cancer Res 74 2014 3652 3658
21. R. Iannone, L. Miele, P. Maiolino, A. Pinto, and S. Morello Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model Am J Cancer Res 4 2014 172 181
22. A.T. Waickman, A. Alme, L. Senaldi, P.E. Zarek, M. Horton, and J.D. Powell Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor Cancer Immunol Immunother 61 2011 917 926
23. M. Turcotte, K. Spring, S. Pommey, G. Chouinard, I. Cousineau, J. George, G.M. Chen, D.M.A. Gendoo, B. Haibe-Kains, T. Karn, and et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer Cancer Res 75 2015 4494 4503
24. S. Loi, S. Pommey, B. Haibe-Kains, P.A. Beavis, P.K. Darcy, M.J. Smyth, and J. Stagg CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer Proc Natl Acad Sci U S A 110 2013 11091 11096
25. P.A. Beavis, U. Divisekera, C. Paget, M.T. Chow, L.B. John, C. Devaud, K. Dwyer, J. Stagg, M.J. Smyth, and P.K. Darcy Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors Proc Natl Acad Sci U S A 110 2013 14711 14716
26. S.M. Hatfield, J. Kjaergaard, D. Lukashev, T.H. Schreiber, B. Belikoff, R. Abbott, S. Sethumadhavan, P. Philbrook, K. Ko, R. Cannici, and et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation Sci Transl Med 7 2015 277ra30
27. L. Wang, J. Fan, L.F. Thompson, Y. Zhang, T. Shin, T.J. Curiel, and B. Zhang CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice J Clin Invest 121 2011 2371 2382
28. A. Ohta, E. Gorelik, S.J. Prasad, F. Ronchese, D. Lukashev, M.K.K. Wong, X. Huang, S. Caldwell, K. Liu, P. Smith, and et al. A2A adenosine receptor protects tumors from antitumor T cells Proc Natl Acad Sci U S A 103 2006 13132 13137
29. P. Pellegatti, L. Raffaghello, G. Bianchi, F. Piccardi, V. Pistoia, and F.D. Virgilio Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase PLoS ONE 3 2008 e2599
30. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel Immunogenic cell death in cancer therapy Annu Rev Immunol 31 2013 51 72
31. L. Aymeric, L. Apetoh, F. Ghiringhelli, A. Tesniere, I. Martins, G. Kroemer, M.J. Smyth, and L. Zitvogel Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity Cancer Res 70 2010 855 858
32. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, and et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors Nat Med 15 2009 1170 1178
33. M.V. Sitkovsky, S. Hatfield, R. Abbott, B. Belikoff, D. Lukashev, and A. Ohta Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists Cancer Immunol Res 2 2014 598 605
34. S.M. Hatfield, J. Kjaergaard, D. Lukashev, B. Belikoff, T.H. Schreiber, S. Sethumadhavan, R. Abbott, P. Philbrook, M. Thayer, D. Shujia, and et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection J Mol Med 92 2014 1283 1292
35. J.M. Poth, K. Brodsky, H. Ehrentraut, A. Grenz, and H.K. Eltzschig Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease J Mol Med 91 2012 183 193
36. H.K. Eltzschig, D. Köhler, T. Eckle, T. Kong, S.C. Robson, and S.P. Colgan Central role of Sp1-regulated CD39 in hypoxia/ischemia protection Blood 113 2009 224 232
37. H.K. Eltzschig, J.C. Ibla, G.T. Furuta, M.O. Leonard, K.A. Jacobson, K. Enjyoji, S.C. Robson, and S.P. Colgan Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors J Exp Med 198 2003 783 796
38. K. Synnestvedt, G.T. Furuta, K.M. Comerford, N. Louis, J. Karhausen, H.K. Eltzschig, K.R. Hansen, L.F. Thompson, and S.P. Colgan Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia J Clin Invest 110 2002 993 1002
39. A. Ahmad, S. Ahmad, L. Glover, S.M. Miller, J.M. Shannon, X. Guo, W.A. Franklin, J.P. Bridges, J.B. Schaack, S.P. Colgan, and et al. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells Proc Natl Acad Sci U S A 106 2009 10684 10689
40. T. Kong, K.A. Westerman, M. Faigle, H.K. Eltzschig, and S.P. Colgan HIF-dependent induction of adenosine A2B receptor in hypoxia FASEB J Off Publ Fed Am Soc Exp Biol 20 2006 2242 2250
41. J.C. Morote-Garcia, P. Rosenberger, J. Kuhlicke, and H.K. Eltzschig HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak Blood 111 2008 5571 5580
42. H.K. Eltzschig, P. Abdulla, E. Hoffman, K.E. Hamilton, D. Daniels, C. Schönfeld, M. Löffler, G. Reyes, M. Duszenko, J. Karhausen, and et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia J Exp Med 202 2005 1493 1505
43. U.K.M. Decking, G. Schlieper, K. Kroll, and J. Schrader Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release Circ Res 81 1997 154 164
44. S. Narravula, P.F. Lennon, B.U. Mueller, and S.P. Colgan Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function J Immunol 165 2000 5262 5268
45. G.C. Sim, N. Martin-Orozco, L. Jin, Y. Yang, S. Wu, E. Washington, D. Sanders, C. Lacey, Y. Wang, L. Vence, and et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients J Clin Invest 124 2014 99 110
46. L.D. Christensen, V. Andersen, P. Nygaard, and K. Bendtzen Effects of immunomodulators on ecto-5′-nucleotidase activity on blood mononuclear cells in vitro Scand J Immunol 35 1992 407 413
47. K. Kalsi, C. Lawson, M. Dominguez, P. Taylor, M.H. Yacoub, and R.T. Smolenski Regulation of ecto-5′-nucleotidase by TNF-α in human endothelial cells Mol Cell Biochem 232 2002 113 119
48. J. Niemelä, T. Henttinen, G.G. Yegutkin, L. Airas, A.-M. Kujari, P. Rajala, and S. Jalkanen IFN-α induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′-nucleotidase) up-regulation J Immunol 172 2004 1646 1653
49. J. Kiss, G.G. Yegutkin, K. Koskinen, T. Savunen, S. Jalkanen, and M. Salmi IFN-β protects from vascular leakage via up-regulation of CD73 Eur J Immunol 37 2007 3334 3338
50. F. Chalmin, G. Mignot, M. Bruchard, A. Chevriaux, F. Végran, A. Hichami, S. Ladoire, V. Derangère, J. Vincent, D. Masson, and et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression Immunity 36 2012 362 373
51. M. Thibaudin, M. Chaix, R. Boidot, F. Végran, V. Derangère, E. Limagne, H. Berger, S. Ladoire, L. Apetoh, and F. Ghiringhelli Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions Oncoimmunology 5 2016 e1055444
52. F.S. Regateiro, D. Howie, K.F. Nolan, E.I. Agorogiannis, D.R. Greaves, S.P. Cobbold, and H. Waldmann Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-β Eur J Immunol 41 2011 2955 2965
53. S.V. Ryzhov, M.W. Pickup, A. Chytil, A.E. Gorska, Q. Zhang, P. Owens, I. Feoktistov, H.L. Moses, and S.V. Novitskiy Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors J Immunol 193 2014 3155 3164
54. J. Spychala, and J. Kitajewski Wnt and β-catenin signaling target the expression of ecto-5′-nucleotidase and increase extracellular adenosine generation Exp Cell Res 296 2004 99 108
55. E. Nevedomskaya, R. Perryman, S. Solanki, N. Syed, O.A. Mayboroda, and H.C. Keun A systems oncology approach identifies NT5E as a key metabolic regulator in tumor cells and modulator of platinum sensitivity J Proteome Res 15 2016 280 290
56. R.T. Lawrence, E.M. Perez, D. Hernández, C.P. Miller, K.M. Haas, H.Y. Irie, S.-I. Lee, C.A. Blau, and J. Villén The proteomic landscape of triple-negative breast cancer Cell Rep 11 2015 630 644
57. N. Sunaga, D.S. Shames, L. Girard, M. Peyton, J.E. Larsen, H. Imai, J. Soh, M. Sato, N. Yanagitani, K. Kaira, and et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy Mol Cancer Ther 10 2011 336 346
58. C. Lo Nigro, M. Monteverde, S. Lee, L. Lattanzio, D. Vivenza, A. Comino, N. Syed, A. McHugh, H. Wang, C. Proby, and et al. NT5E CpG island methylation is a favourable breast cancer biomarker Br J Cancer 107 2012 75 83
59. H. Wang, S. Lee, C.L. Nigro, L. Lattanzio, M. Merlano, M. Monteverde, R. Matin, K. Purdie, N. Mladkova, D. Bergamaschi, and et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity Br J Cancer 106 2012 1446 1452
60. S. Serra, A.L. Horenstein, T. Vaisitti, D. Brusa, D. Rossi, L. Laurenti, G. D'Arena, M. Coscia, C. Tripodo, G. Inghirami, and et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death Blood 118 2011 6141 6152
61. S.F.M. Häusler, I.M. del Barrio, J. Strohschein, P.A. Chandran, J.B. Engel, A. Hönig, M. Ossadnik, E. Horn, B. Fischer, M. Krockenberger, and et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity Cancer Immunol Immunother 60 2011 1405 1418
62. M. Mandapathil, M.J. Szczepanski, M. Szajnik, J. Ren, D.E. Lenzner, E.K. Jackson, E. Gorelik, S. Lang, J.T. Johnson, and T.L. Whiteside Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer Clin Cancer Res 15 2009 6348 6357
63. S. Ryzhov, S.V. Novitskiy, A.E. Goldstein, A. Biktasova, M.R. Blackburn, I. Biaggioni, M.M. Dikov, and I. Feoktistov Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells J Immunol 187 2011 6120 6129
64. I. Shevchenko, A.V. Bazhin, and V. Umansky Comment on "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells" J Immunol 188 2012 2929 2930
65. B. Allard, M. Turcotte, K. Spring, S. Pommey, I. Royal, and J. Stagg Anti-CD73 therapy impairs tumor angiogenesis Int J Cancer 134 2014 1466 1473
66. L. Wang, S. Tang, Y. Wang, S. Xu, J. Yu, X. Zhi, Z. Ou, J. Yang, P. Zhou, and Z. Shao Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis Clin Exp Metastasis 30 2013 671 680
67. M. Mediavilla-Varela, K. Luddy, D. Noyes, F.K. Khalil, A.M. Neuger, H. Soliman, and S.J. Antonia Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth Cancer Biol Ther 14 2013 860 868
68. C. Sattler, M. Steinsdoerfer, M. Offers, E. Fischer, R. Schierl, K. Heseler, W. Däubener, and J. Seissler Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation Cell Transplant 20 2011 1221 1230
69. E. Kerkelä, A. Laitinen, J. Räbinä, S. Valkonen, M. Takatalo, A. Larjo, J. Veijola, M. Lampinen, P. Siljander, P. Lehenkari, and et al. Adenosinergic immunosuppression by human mesenchymal stromal cells requires co-operation with T cells Stem Cells 2016 10.1002/stem.2280
70. P.J. Schuler, Z. Saze, C.-S. Hong, L. Muller, D.G. Gillespie, D. Cheng, M. Harasymczuk, M. Mandapathil, S. Lang, E.K. Jackson, and et al. Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells Clin Exp Immunol 177 2014 531 543
71. S. Xu, Q.-Q. Shao, J.-T. Sun, N. Yang, Q. Xie, D.-H. Wang, Q.-B. Huang, B. Huang, X.-Y. Wang, X.-G. Li, and et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas Neuro Oncol 2013 10.1093/neuonc/not067
72. A. Clayton, S. Al-Taei, J. Webber, M.D. Mason, and Z. Tabi Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production J Immunol 187 2011 676 683
73. L.A. Smyth, K. Ratnasothy, J.Y.S. Tsang, D. Boardman, A. Warley, R. Lechler, and G. Lombardi CD73 expression on extracellular vesicles derived from CD4+CD25+Foxp3+ T cells contributes to their regulatory function Eur J Immunol 43 2013 2430 2440
74. L. Muller, M. Mitsuhashi, P. Simms, W.E. Gooding, and T.L. Whiteside Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets Sci Rep 6 2016
75. Y. Yang, V. Bucan, H. Baehre, J. von der Ohe, A. Otte, and R. Hass Acquisition of new tumor cell properties by MSC-derived exosomes Int J Oncol 47 2015 244 252
76. D. Chatterjee, D.M. Tufa, H. Baehre, R. Hass, R.E. Schmidt, and R. Jacobs Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells Blood 123 2014 594 595
77. A.L. Horenstein, A. Chillemi, G. Zaccarello, S. Bruzzone, V. Quarona, A. Zito, S. Serra, and F. Malavasi A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes Oncoimmunology 2 2013 e26246
78. S.E. Street, N.J. Kramer, P.L. Walsh, B. Taylor-Blake, M.C. Yadav, I.F. King, P. Vihko, R.M. Wightman, J.L. Millán, and M.J. Zylka Tissue-nonspecific alkaline phosphatase acts redundantly with PAP and NT5E to generate adenosine in the dorsal spinal cord J Neurosci 33 2013 11314 11322
79. S.V. Novitskiy, S. Ryzhov, R. Zaynagetdinov, A.E. Goldstein, Y. Huang, O.Y. Tikhomirov, M.R. Blackburn, I. Biaggioni, D.P. Carbone, I. Feoktistov, and et al. Adenosine receptors in regulation of dendritic cell differentiation and function Blood 112 2008 1822 1831
80. C. Cekic, D. Sag, Y. Li, D. Theodorescu, R.M. Strieter, and J. Linden Adenosine A2B receptor blockade slows growth of bladder and breast tumors J Immunol 188 2012 198 205
81. J. Stagg, P.A. Beavis, U. Divisekera, M.C.P. Liu, A. Möller, P.K. Darcy, and M.J. Smyth CD73-deficient mice are resistant to carcinogenesis Cancer Res 72 2012 2190 2196
82. B.G. Leclerc, R. Charlebois, G. Chouinard, B. Allard, S. Pommey, F. Saad, and J. Stagg CD73 expression is an independent prognostic factor in prostate cancer Clin Cancer Res 22 2016 158 166
83. P.E. Zarek, C.-T. Huang, E.R. Lutz, J. Kowalski, M.R. Horton, J. Linden, C.G. Drake, and J.D. Powell A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells Blood 111 2008 251 259
84. M. Romio, B. Reinbeck, S. Bongardt, S. Hüls, S. Burghoff, and J. Schrader Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells Am J Physiol Cell Physiol 301 2011 C530 C539
85. T. Raskovalova, A. Lokshin, X. Huang, E.K. Jackson, and D.E. Gorelik Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells Immunol Res 36 2006 91 99
86. A. Ohta, M. Madasu, M. Subramanian, R. Kini, G. Jones, A. Choukèr, A. Ohta, and M. Sitkovsky Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible Int Immunol 26 2014 83 91
87. S. Deaglio, K.M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J.-F. Chen, K. Enjyoji, J. Linden, M. Oukka, and et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression J Exp Med 204 2007 1257 1265
88. A. Ohta, R. Kini, A. Ohta, M. Subramanian, M. Madasu, and M. Sitkovsky The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway Front Immunol 3 2012
89. G.R. Kinsey, L. Huang, K. Jaworska, K. Khutsishvili, D.A. Becker, H. Ye, P.I. Lobo, and M.D. Okusa Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection J Am Soc Nephrol 23 2012 1528 1537
90. H. Ehrentraut, J.A. Westrich, H.K. Eltzschig, and E.T. Clambey Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation PLoS ONE 7 2012 e32416
91. A. Lokshin, T. Raskovalova, X. Huang, L.C. Zacharia, E.K. Jackson, and E. Gorelik Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells Cancer Res 66 2006 7758 7765
92. R. Iannone, L. Miele, P. Maiolino, A. Pinto, and S. Morello Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma Neoplasia 15 2013 1400 1410
93. C. Sorrentino, L. Miele, A. Porta, A. Pinto, and S. Morello Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model Oncotarget 6 2015 27478 27489
94. C. Cekic, Y.-J. Day, D. Sag, and J. Linden Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment Cancer Res 74 2014 7250 7259
95. M.G. Terp, K.A. Olesen, E.C. Arnspang, R.R. Lund, B.C. Lagerholm, H.J. Ditzel, and R. Leth-Larsen Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells J Immunol 191 2013 4165 4173
96. J. Bastid, A. Regairaz, N. Bonnefoy, C. Dejou, J. Guistiniani, C. Laheurte, S. Cochaud, E. Laprevotte, E. Funck-Brentano, P. Hemon, and et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity Cancer Immunol Res 2014 10.1158/2326-6066.CIR-14-0018
97. G.M. Hayes, B. Cairns, Z. Levashova, L. Chinn, M. Perez, J.-W. Theunissen, S. Liao-Chan, A. Bermudez, M.R. Flory, K.J. Schweighofer, and et al. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma Am J Transl Res 7 2015 1181 1188
98. C.J. Desmet, T. Gallenne, A. Prieur, F. Reyal, N.L. Visser, B.S. Wittner, M.A. Smit, T.R. Geiger, J. Laoukili, S. Iskit, and et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis Proc Natl Acad Sci U S A 110 2013 5139 5144
99. E. Ntantie, P. Gonyo, E.L. Lorimer, A.D. Hauser, N. Schuld, D. McAllister, B. Kalyanaraman, M.B. Dwinell, J.A. Auchampach, and C.L. Williams An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering Sci Signal 6 2013 ra39
100. B.C. Barnhart, E. Sega, A. Yamniuk, S. Hatcher, M. Lei, H. Ghermazien, A. Lewin, X.T. Wang, H. Huang, P. Zhang, and A. Korman A therapeutic antibody that inhibits CD73 activity by dual mechanisms Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, AACR; Abstract 1476 April 16-20, 2016, New Orleans, LA 2016
101. A. Antonini, and W. Poewe Adenosine A2A receptor antagonists in Parkinson's disease: still in the running Lancet Neurol 13 2014 748 749
102. C. Cekic, and J. Linden Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment Cancer Res 74 2014 7239 7249
103. B. Gyorffy, P. Surowiak, J. Budczies, and A. Lánczky Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer PLOS ONE 8 2013 e82241
104. I. Melero, D.M. Berman, M.A. Aznar, A.J. Korman, J.L.P. Gracia, and J. Haanen Evolving synergistic combinations of targeted immunotherapies to combat cancer Nat Rev Cancer 15 2015 457 472
105. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 2015 23 34
106. I. Verbrugge, J. Hagekyriakou, L.L. Sharp, M. Galli, A. West, N.M. McLaughlin, H. Duret, H. Yagita, R.W. Johnstone, M.J. Smyth, and et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies Cancer Res 72 2012 3163 3174
107. E. Wennerberg, N. Kawashima, and S. Demaria Adenosine regulates radiation therapy-induced anti-tumor immunity J Immunother Cancer 3 2015 378